This study aimed to assess the smallest clinical target volume (CTV) to planned target volume (PTV) margins for esophageal cancer radiotherapy using daily online registration to the bony anatomy that yield full dosimetric coverage over the course of treatment. 29 esophageal cancer patients underwent six T2-weighted MRI scans at weekly intervals. An online bone-match image-guided radiotherapy treatment of five fractions was simulated for each patient. Multiple conformal treatment plans with increasing margins around the CTV were created for each patient. https://www.selleckchem.com/products/pfk15.html Then, the dose was warped to obtain an accumulated dose per simulated fraction. Full target coverage by 95% of the prescribed dose was assessed as a function of margin expansion in six directions. If target coverage in a single direction was accomplished, then the respective margin remained fixed for the subsequent dose plans. Margins in uncovered directions were increased in a new dose plan until full target coverage was achieved. The smallest set of CTctively, are sufficient to account for interfraction tumor variations over the course of treatment when applying a daily online bone match. However, two patients with extreme esophageal interfraction motion were insufficiently covered with these margins and were identified as patients requiring replanning to achieve full target coverage. To quantitate the accuracy, reproducibility and prostate motion mitigation efficacy rendered by a target immobilization method used in an intermediate-risk prostate cancer dose-escalated 5×9Gy SBRT study. An air-inflated (150cm ) endorectal balloon and Foley catheter with three electromagnetic beacon transponders (EBT) were used to mitigate and track intra-fractional target motion. A 2mm margin was used for PTV expansion, reduced to 0mm at the interface with critical OARs. EBT-detected≥2mm/5s motions mandated treatment interruption and target realignment prior to completion of planned dose delivery. Geometrical uncertainties were measured with an in-house ESAPI script. Quantitative data were obtained in 886 sessions from 189 patients. Mean PTV dose was 45.8±0.4Gy (D95=40.5±0.4Gy). A mean of 3.7±1.7 CBCTs were acquired to reach reference position. Mean treatment time was 19.5±12min, 14.1±11 and 5.4±5.9min for preparation and treatment delivery, respectively. Target motion of 0, 1-2 and >2mm/10min were observed in 59%, 30% and 11% of sessions, respectively. Temporary beam-on hold occurred in 7.4% of sessions, while in 6% a new reference CBCT was required to correct deviations. Hence, all sessions were completed with application of the planned dose. Treatment preparation time>15min was significantly associated with the need of a second reference CBCT. Overall systematic and random geometrical errors were in the order of 1mm. The prostate immobilization technique explored here affords excellent accuracy and reproducibility, enabling normal tissue dose sculpting with tight PTV margins. The prostate immobilization technique explored here affords excellent accuracy and reproducibility, enabling normal tissue dose sculpting with tight PTV margins. To train a deep neural network for correcting abdominal and pelvic cone-beam computed tomography (CBCT) of children and young adults in the presence of diverse patient size, anatomic extent, and scan parameters. Pretreatment CBCT and planning/repeat CT image pairs from 64 children and young adults treated with proton therapy (aged 1-23years) were analyzed. To evaluate the impact of anatomic extent in CBCT and data size in the training data, we compared the performance of three cycle-consistent generative adversarial network models that were separately trained by three datasets comprising abdominal (n=21), pelvic (n=29), and combined abdominal-pelvic image pairs (n=50), respectively. The maximum body width of each patient was normalized to a fixed width before training and model application to reduce the impact of variations in body size. The corrected CBCT images by the three models were comparatively evaluated against the repeat CT closest in time to the CBCT (median gap, 0days; range, 0-6days) in HU acc in training a neural network to accurately estimate proton dose from CBCT despite limited training data size and anatomic diversities.It has been reported that citicoline increases antioxidant activity in some tissues. However, the effect of citicoline on corneal wound-healing has not yet been demonstrated. The aim was to investigate the protective effects of citicoline on ultraviolet B (UVB) radiation-induced corneal oxidative damage in a rat model. Four groups (eight animals each) were investigated controls; UVB only; UVB/citicoline; and citicoline only. Corneal oxidative damage was induced by exposure to UVB radiation at 560 μW/cm2 for five days in the UVB-exposed groups and 1% citicoline eye drops were applied (3xday) for eight days in the two citicoline groups. Corneal surface damage was evaluated by opacity and fluorescein staining. Corneal injury was assessed biochemically by measuring the concentrations of glutathione (GSH) and malondialdehyde (MDA) and the activity of corneal superoxide dismutase (SOD) and catalase. Matrix metalloproteinase (MMP) -2 and -9 and caspase-3 were evaluated by immunofluorescent staining and microscopic etment may be effective in suppressing oxidative stress and controlling inflammation in UVB corneal injury. Corneal fibroblast can be transformed into corneal myofibroblasts by TGF-β1. Enhancer of zeste homolog 2 (EZH2) upregulation has been observed in the occurrence of other fibrotic disorders. We investigated the role of EZH2 in the progression of corneal fibrosis and the antifibrotic effect of EZH2 inhibition in corneal fibroblasts (CFs). Primary CFs were isolated from corneal limbi and the CFs were treated with TGF-β1 to induce fibrosis. EPZ-6438 and EZH2 siRNA were used to inhibit EZH2 expression. Myofibroblast activation and extracellular matrix (ECM) protein synthesis was detected by quantitative real-time PCR, western blotting, and immunofluorescence staining assay. The functions of myofibroblast were evaluated by cell migration and collagen gel contraction assays. Molecular mechanisms involved in EZH2 inhibition were investigated by RNA sequencing. TGF-β1 activated EZH2 expression in CFs. Treatment with EPZ-6438 (5μM) and EZH2 siRNA considerably suppressed corneal myofibroblast activation and ECM protein synthesis in CFs induced by TGF-β1 when compared to the control group.